Showing 1331-1340 of 1616 results for "".
- Aurion Makes Leadership Announcementshttps://modernod.com/news/aurion-makes-leadership-announcements/2482757/Aurion Biotech announced the appointments of Edward J. Holland, MD, as Chief Medical Officer, and Eris P. Jordan, OD, as Chief Development Officer. Aurion is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema seconda
- Fred Moll, Founder of Intuitive Surgical, Joins ForSight Robotics Board of Directorshttps://modernod.com/news/fred-moll-founder-of-intuitive-surgical-joins-forsight-robotics-board-of-directors/2482664/ForSight Robotics announced that Fred Moll, MD, the founder of Intuitive Surgical, has joined its Board of Directors. Intuitive Surgical is the company behind the da Vinci surgical system, the first robotic surgical platform commercially available in the US 
- Iantrek Appoints Adam Szaronos as Chief Executive Officerhttps://modernod.com/news/iantrek-appoints-adam-szaronos-as-chief-executive-officer/2482644/Iantrek announced the appointment of Adam Szaronos as its new Chief Executive Officer. Mr. Szaronos succeeds company founder Sean Ianchulev, MD, MPH, who will remain as Chairman of the Board and Chief Medical Officer. “Iantrek has reached an exciting milestone as we transitio
- Rayner Completes Recruitment for RayOne Galaxy IDE Studyhttps://modernod.com/news/rayner-completes-recruitment-for-rayone-galaxy-ide-study/2482642/Rayner announced the closure of recruitment in the Investigational Device Exemption (IDE) study for the RayOne Galaxy IOL in the United States. Developed in collaboration with Brazilian ophthalmologist João Lyra, MD, PhD, RayOne Galaxy is the worl
- Tangible Science Announces CEO Transitionhttps://modernod.com/news/tangible-science-announces-ceo-transition/2482613/Tangible Science, a provider of specialty contact lens technology, announced that Karen Havenstrite, PhD, MBA, co-founder and former Chief Technology Officer, has been appointed Chief Executive Officer. Dr. Havenstrite suceeds Victor McCray, MD, who will transition to the
- Myze Launches 'The Daily Lid Wipe' for Eyelid Hygienehttps://modernod.com/news/myze-launches-the-daily-lid-wipe-to-elevate-daily-eye-care-partnering-with-leading-eye-health-experts/2482543/In a move to prioritize eyelid hygiene and make it a core component of everyday self-care routine, myze has unveiled its first branded product, The Daily Lid Wipe. The Daily Lid Wipe, formulated with input from dry eye experts Laura M. Periman, MD, and Cecelia Koett
- Oklahoma Neonatologist-Researcher Earns NIH Grant to Advance Retinopathy of Prematurityhttps://modernod.com/news/oklahoma-neonatologist-researcher-earns-nih-grant-to-advance-retinopathy-of-prematurity/2482537/Faizah Bhatti, MD, was the first to discover the presence of surfactant protein A in the eye–a key protein related to blood vessel growth and previously believed to only exist in the lung. Now, the University of Oklahoma neonatologist and researcher has earned a 5-year, $2.3 million grant f
- Epion Presents Survey on Keratoconus Highlighting Need for Accessible Treatmentshttps://modernod.com/news/epion-presents-survey-on-keratoconus-highlighting-urgent-need-for-accessible-treatments/2482518/Jonathan H. Talamo, MD, Chair of the Board at Epion Therapeutics, presented findings at the Eyecelerator@AAO 2024 conference on the current state of keratoconus (KC) management in the United States, highlighting a critical gap in treatment for the progressive eye disease. Results f
- Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024https://modernod.com/news/oculis-to-provide-update-on-diamond-phase-3-program-for-ocs-01-eye-drops-at-innovate-retina-and-eyecelerator-2024/2482488/Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME). David Eichenbaum, MD, an expert in retina diseases, will present new insig
- 4DMT Announces Phase 2 PRISM Interim Results for Intravitreal 4D-150 in Wet AMDhttps://modernod.com/news/4dmt-announces-phase-2-prism-interim-results-for-intravitreal-4d-150-in-wet-amd/2482364/4D Molecular Therapeutics announced initial interim 24-week landmark data from the population extension cohort of the PRISM phase 2 clinical trial, which evaluated intravitreal 4D-150 in a broad wet AMD patient population. The data were presented by Raj K. Maturi, MD, at the A